1. Introduction {#S1}
===============

Given the evolutionary closeness of non-human primates (NHP) to humans it is not surprising that there is strong structural conservation between human and non-human nicotinic acetylcholine receptors (nAChRs). The combination of conservation of nAChR structure and conservation of complex behaviors between non-human primates and humans makes non-human primates a valuable model for studies of the roles of nAChR in a variety of behaviors and for evaluation of potential therapeutics. Indeed, advancing neuro-therapeutics to market has proven problematic with drugs targeting the CNS due to longer development times and higher clinical trial failure rates when compared to other drug categories ([@R38]; [@R36]; [@R58]). One aspect of the challenge is the greater functional difference between rodent and human brain than exists for other systems or organs such as cardiovascular or renal. This reflects both differences in anatomy and specificity and distribution of receptors for ligands. For example, the prefrontal cortex, which plays a key regulatory role in addictive behavior, is significantly underdeveloped in rodents compared to primates ([@R70]). In terms of ligands, varenicline is significantly more potent against human than rat α3β4, while cytisine is significantly less potent against human than rat α3β4 ([@R64]). Similarly the most specific and potent antagonist for the α9α10 nAChR, α-conotoxin (α-CTx) RgIA, is 300-fold less potent against human than rat α9α10 ([@R4]) and this difference in potency derives from a single amino acid change (T56I). Thus non-human primate (NHP) models, in which neuroanatomy and nAChR receptors are more homologous to humans, will likely be essential for the development of the next generation of smoking cessation therapies.

The advent of low cost, whole genome sequencing has greatly expanded available information about NHP nAChRs. Currently available NHP genome assemblies in public databases include baboon, bonobo, bushbaby, chimpanzee, cynomolgus monkey, gibbons, guerilla, lemurs, marmoset, orangutan, rhesus monkey, squirrel monkey, tarser, vervet (<http://www.ncbi.nlm.nih.gov/genome/browse/>) and more are being added all the time. The sequencing of large pedigreed NHP colonies further opens up possibilities for studying the roles of nAChR in non-human primates particularly linking gene function and polymorphisms to behaviors and quantitative traits. In addition the conservation of key polymorphisms between monkeys and humans, such as in the serotonin transporter and monamine oxidase further emphasizes species similarities and the potential for research discoveries ([@R72]; [@R5]).

2. Non-human primate nicotinic receptor structure and organization {#S2}
==================================================================

2.1. Genomic Structure {#S3}
----------------------

The nAChR subunit genes are divided into subfamilies and tribes based on sequence similarity ([@R19]). The α9 and α10 subunits, each encoded by 5 exons, are the most recently cloned nAChR subunits and comprise neuronal nAChR subfamily I. The α7 subunit (neuronal subfamily II) has the most dissimilar genomic structure of all mammalian nAChR genes and is composed of 10 exons, 9 of which are smaller than 200 bp. This subunit more closely resembles the muscle type nAChRs and is likely an ancestral subunit that existed prior to the divergence of insects and vertebrates ([@R44]).

We conducted a comparative analysis of the genomic structures of nAChR subunits between the rhesus and human genomes. We retrieved the genomic sequence of human nAChR subunits using the UCSC Genome Bioinformatics Site ([@R39]). The UCSC Table Browser was used to extract the sequence and structural information of nAChR subunit genes (i.e. chromosomal position, exon start and end positions) from the human hg19 genome build. For rhesus macaque, we used the RefSeq gene annotations when available from the rheMac2 genome to determine the sequence, size and position of coding exons and to calculate length of exonic and intronic sequences. The intron and UTR sizes in rhesus macaque were approximated for some nAChR subunits as the available draft assemblies (rheMac2 and rheMac3) contain gaps, denoted by " ..NNN...", that are of unknown true length. The Basic Local Alignment Search Tool (BLAST) was then used to align the extracted human and rhesus nucleotide sequences, optimized for highly similar sequences (megablast). Using this approach, we observed high homology between human and rhesus nAChR exon regions. In instances where RefSeq annotations were unavailable for rhesus genomes we manually compared regions of human sequence to equivalent regions of rhesus genomes on a base-by-base level. Overall, the genomic structure of nAChR subunits was highly conserved between rhesus and human as shown in [Table 1](#T1){ref-type="table"}.

In humans, there exists a partial duplication of the gene encoding the α7 subunit (*CHRNA7*), known as *CHRFAM7*, which functions as a dominant negative regulator of α7 nAChR ([@R3]). This fusion gene is comprised of 1 exon of unknown origin, 3 exons of *ULK4*, and exons 5 through 10 of *CHRNA7* ([@R3]). This duplication event has been proposed to be human specific based on southern blot analysis in chimpanzee and gorilla ([@R46]) and the high level of homology with human *CHRNA7*. We used *in silico* BLAT analysis ([@R37]; [@R39]) to look for similar duplication events in the available primate genomes. As proof of principle, we first queried the genomic sequence of human *CHRNA7* exons 5--10 (14548 bp) against hg19 which resulted in two alignments of similar size and identity: to *CHRNA7* with 100% identity and to *CHRFAM7* with 99.8% identity. Using the same approach, we confirmed only single high-homology alignments (to *CHRNA7*) in all primate genomes available in the BLAT tool (baboon, chimp, bushbaby, gibbon, orangutan, squirrel monkey) except gorilla. Here we saw substantial alignment (98.4% and 98.2%) of the human query at two positions on the gorGor3 genome (chr15minus:8,824,749-8,835,892 and chr15plus:10,541,866-10,552,122) spanning 13528 and 14053 bp, respectively, indicating that there may be a partial duplication event in gorilla as well. Further suggesting that gorillas may well express *CHRFAM7*, a portion of the *ULK4* gene appears to align next to the duplicate copy of *CHRNA7*. However, the relatively poor quality of the Gor3 genome assembly prevents a definitive statement regarding the existence of *CHRFAM7A* in gorillas at this time.

2.2. Protein Structure {#S4}
----------------------

Nicotinic acetylcholine receptors are members of the Cys-loop superfamily of ligand-gated ion channels. Characteristic of this class, nAChRs are composed of five transmembrane protein subunits arranged in a ring to form a central ion pore ([@R67]). These protein subunits are classified as either alpha or beta subunits based on the presence of two adjacent cysteine residues in alpha subunits in the N-terminal extracellular domain ([@R47]). Presently, 8 alpha subunits (α2, α3, α4, α5, α6, α7, α9, α10) and 3 beta subunits have been identified in the mammalian central nervous system ([@R1]). These nAChR subunit proteins range in length from 458 to 627 amino acids (human) with a well-conserved order of structural domains that define their placement within the cellular membrane. Each subunit begins with an N-terminal extracellular domain, followed by three transmembrane domains, a large intracellular loop, a fourth transmembrane domain, and finally a short C-terminal extracellular domain. The transmembrane domains are highly conserved while the large intracellular loop is the most variable region between subunits ([@R56]). Functional heteromeric receptors contain at least two alpha subunits and the subunit composition and stoichiometry of nAChRs determines ligand binding affinity and specificity as well as ion channel permeability ([@R1]). The α7 subunits form primarily homopentamers while a diverse array of functional heteromers can be formed by various combinations of neuronal subfamily III.1 subunits (α2, α3, α4, and α6) with subfamily III.2 subunits (β2, β4) that may also include subfamily III.3 subunits (α5 and β3). The α5 and β3 subunits are unique in that they are structural or "accessory" subunits, and do not contribute to ligand binding but can greatly modulate receptor pharmacology ([@R43]). Because the true composition and stoichiometry of receptor subunits *in vivo* is often not known the presence of additional "wild-card" subunits is denoted by an asterisk (i.e. α4β2\*). Lastly, the α9 subunit can form functional receptors in recombinant expression systems, but is believed to form heteromers with the closely related α10 subunit, which appears to play a structural role ([@R57]).

2.3. Homology of primate nAChRs to human nAChRs {#S5}
-----------------------------------------------

We assessed the homology of primate nAChRs to human using CDS Fasta alignment sequences retrieved from the UCSC table browser (<https://genome.ucsc.edu/>). The current CDS FastA alignment data set includes the following primate reference genomes: chimpanzee (panTro4), gorilla (gorGor3), orangutan (ponAbe2), gibbon (nomLeu3), rhesus macaque (rheMac3), cynomolgus or crab-eating macaque (macFas5), baboon (papHam1), green monkey (chlSab1), marmoset (calJac3), squirrel monkey (saiBol1), and bushbaby (otoGar3). We calculated percent similarity of non-human primate nAChRs with human using MegAlign ClustalW alignment of coding sequences. One limitation of this data is that a number of gaps exist in the publically available primate reference sequences. Therefore we removed gap penalties in our alignment settings to demonstrate homology only in non-gap coding regions and inserted our own sequencing data when available to fill gaps. Otherwise, the default Multiple-Alignment Parameter settings were selected with Gonnet Series weighting. Averaging across all neuronal nAChRs, conservation of great apes, old world monkeys, and new world monkeys with humans is 98.9%, 97.5%, and 94.2%, respectively at the protein level. This is in contrast to conservation of 88.9% for mice with humans. The primate α7 (98.9%) and β2 (98.7%) had the highest homology with human subunit coding sequence while α4 (95.5%) and β4 (95.5%) had the lowest, as shown in [Table 2](#T2){ref-type="table"}. Within the nAChR subunit genes we most commonly observed small gaps in the N-terminal region that encodes the signal peptide. These regions are often CpG rich which are resistant to standard high throughput sequencing procedures due to secondary structure formation. The α4 subunit sequence exhibited the highest number of genome assembly sequence gaps with incomplete coding sequence for orangutan, chimpanzee, gorilla, gibbon, rhesus, bushbaby, and marmoset. Given that the α4β2 containing receptors are the most predominant nAChR subtypes in mammalian brain and that these and additional nAChR subunits contribute to the behavioral effects of nicotine it is clearly important to fill these sequencing gaps.

2.4. Conservation of polymorphisms between NHP and humans {#S6}
---------------------------------------------------------

While primates share a common genetic structure on the macro-scale, advances in whole-genome sequencing technologies have allowed for the study of population diversity at single nucleotide resolution. The subject of genetic diversity within humans is highly significant as single nucleotide polymorphisms (SNPs) provide key insights into gene function, pathophysiology, and can greatly influence individual responses to therapeutics. The macaques of the Cercopithecidae family of Old World monkeys have been used extensively as translational models with which to study drug pharmacokinetics, safety, and efficacy ([@R8]). The most commonly used model species of this family are the cynomolgus macaques, originating from Southeast Asia, and the rhesus macaques whose territory ranges from Eastern China through Western India and Pakistan ([@R65]). Genetic diversity across these model species influences their behavior, physiology, and phenotypic differences in response to experimental protocols ([@R15]; [@R17]). Greater genetic diversity has been observed in populations of rhesus macaques from China versus those originating from India ([@R20]; [@R74]). One study estimated that rhesus and cynomolgus macaques share approximately half (52%) of SNPs measured in both species ([@R65]). In both the rhesus and cynomolgus macaques, the ratio of non-synonymous/synonymous coding SNPs is significantly lower than in humans ([@R32]). Therefore, despite having greater genetic diversity, the number of damaging non-synonymous polymorphisms in rhesus macaque is estimated to be similar to the number in humans ([@R74]).

2.5. Conservation of single nucleotide polymorphisms in CHRNA5/A3/B4 {#S7}
--------------------------------------------------------------------

Genome-wide association studies (GWAS) and twin studies have indicated a key role for genetics in smoking related phenotypes including cigarettes smoked per day ([@R68]), response to smoking cessation therapy ([@R9]), and smoking related diseases including COPD ([@R26]) and risk of lung cancer ([@R2]). In particular, a number of studies have shown allelic variation in the α5-α3-β4 subunit gene cluster located at human chromosome region 15q25 to be significantly associated with nicotine dependency and smoking-related diseases ([@R61]). One particular single nucleotide polymorphism (SNP) in the α5 subunit gene (rs16969968), in which the amino acid 398 is changed from aspartic acid to asparagine (α5D398N), has been independently validated as a factor in multiple nicotine dependent phenotypes ([@R11]). For example, one study showed that carriers of one copy of rs16969968 smoke on average one additional cigarette per day (CPD) than non-carriers while carriers of two risk alleles smoke on average an additional two CPD, based on objective measures of plasma cotinine ([@R53]). Another study by Lips et al., measured an increased consumption of 0.3 CPD in carriers of one minor allele and an increase of 1.2 CPD in carriers of two risk alleles based on self-reporting of consumption by 17,000 research subjects ([@R45]). This amount may be less than predicted by Manufo et al., due to underreporting of CPD. It is also possible that the association of cotinine levels with α5 genotype is stronger than the association with reported number of cigarettes per day due to genotype effects on smoking topography ([@R48]). Furthermore, rs16969968 is associated with increased risk of lung cancer but the question remains whether the small increase in smoking associated with this polymorphism is sufficient to drive a higher lung cancer incidence.

As the role of increased nicotine addiction versus direct effects of nicotine on cell signaling in the periphery cannot be teased apart in clinical studies, animal models are crucial in order to understand the role of nAChRs in both the brain and periphery. Genetic mouse knock-out models exist for a number of nAChR subunits and have proven invaluable in determining a role for these subunits in nicotine associated behaviors such as dependency, aversion, and withdrawal (for review see ([@R63]; [@R22])). However, homology of mouse nAChR subunits with humans at the protein level is significantly less than NHP model species (88.9% across all subunits for mouse, versus 97.7% for rhesus or cynomolgus macaques). Additionally, complete ablation of a receptor subunit may result in compensation by other subunits and a much different phenotype than a SNP. Finally, in an ideal animal model with which to study the effects of nicotine on brain signaling and behavior, the animal should have similar neuroanatomy, voluntarily self-administer nicotine and metabolize nicotine similarly to humans. Macaque monkeys meet these requirements and have been used extensively by our group and others for study of ethanol, nicotine and other drugs ([@R27]; [@R51]; [@R21]).

To assess the potential of macaque primates for characterizing mechanisms underlying how nAChR polymorphisms affect nicotine dependence and nicotine-mediated pathophysiology, we screened macaque primates for SNPs for comparison with human polymorphisms with particular emphasis on identifying common SNPs with known association to nicotine dependency. In 12 rhesus macaque monkeys (6 of Indian origin, 6 of Chinese origin ([@R20])), we observed 869 SNPs in the α5-α3-β4 cluster (RheMac3 chr7:57,587,673-57,704,684). This region is equivalent in humans to hg19 chr15:78,845,491-78,945,185 which contains 510 SNPs (with an allele frequency ≥1%) according to the UCSC databases "Common SNPs (build138)", respectively. One caveat of this comparison is that the SNP detection pipeline used for our rhesus sequence data was not also used to call SNPs in human sequence data. However, the relatively greater number of SNPs in rhesus macaque vs human at this locus is supported by a previous study which sequenced the 3' end of 94 genes across the rhesus genome and found an average of 1 SNP/107 bp in rhesus compared with 1 SNP/179 bp in human ([@R65]). Across this nAChR gene locus 29 SNP positions are conserved between rhesus and human, however only 10 of these positions share the same reference and variant nucleotide between the two species. Of these 10 conserved SNPs, 1 is in the 5' UTR of *CHRNA5* (human SNP tag rs201545082), 8 are intronic (rs147796977, rs62008248, rs112973744, rs185308922, rs189302121, rs76832402, rs78319611, rs79105076), and 1 is a synonymous SNP in exon 3 of *CHRNA5* (rs75600623). Thus, relatively few rhesus SNPs in this cluster aligned with common human SNPs.

We next assessed the cynomolgus macaque for polymorphisms that may be relevant to nicotine dependent phenotypes. Currently, complete SNP data across the α5-α3-β4 locus for cynomolgus macaques is unavailable. We therefore performed traditional Sanger sequencing across the coding regions of *CHRNA5* in 41 cynomolgus macaques. Primer sequences were designed in Primer 3 against Macaca mulatta to sequence across *CHRNA5* exons. For PCR amplification we used the NEB Flex polymerase system with the following cycling parameters: 92° - 120 seconds; 34 cycles (92° - 30s, 61° −30s, 72° - 60s); 72° - 600s. PCR products were treated with Exonuclease I and Antarctic Phosphatase (37° - 30m, 95° - 5m) prior to sequencing on an Applied Biosystems 3730xl DNA Sequencer. Sequencing results were analyzed in Sequencher software by assembling to the corresponding human exon reference sequence and manually scanning chromatograms for secondary peaks. We identified 6 SNPs in cynomolgus macaque *CHRNA5* exons, 4 of which were non-synonymous SNPs with minor allele frequencies (MAF) ranging between 0.237 and 0.333. Notably cynomolgus macaques, though not rhesus, expressed the same α5 D398N polymorphism that is associated with nicotine dependency and smoking-related diseases in humans (rs16969968). Therefore, using a custom TaqMan allelic discrimination assay we screened an additional 100 animals for this SNP and calculated a minor allele frequency of 0.374 which is similar to the corresponding allele frequency in a population of Utah Residents with Northern and Western European Ancestry (0.385) (HapMap CEU), although neither frequency measure can be considered to be representative of either species as a complete population. However this finding suggests that the polymorphism is relatively common in specific populations of cynomolgus macaques, which makes them a potentially useful model for studies of nicotine dependency and cessation therapies. A second α5 SNP was found in cynomolgus macaques, N346K, which was in linkage disequilibrium with the α5 D398N polymorphism with equivalent major and minor allele frequencies at both loci such that all animals polymorphic for α5 D398N were also polymorphic for α5 N346K. In addition to the α5 D398N polymorphism, a relatively frequent (23% allele frequency) polymorphism in α5 of Thr404Ala was also found in cynomolgus monkeys. This may affect a potential phosphorylation site in cynomolgus α5. Expression of the cynomolgus α5 D398N polymorphism in *xenopus* oocytes and HEK293 cells together with α4β2 subunits showed that the monkey equivalent of the human α5D98N polymorphism produced smaller currents than the wild type cynomolgus α5 similar to the results previously reported for the human polymorphism ([@R41]; [@R12]) ([Figure 1](#F1){ref-type="fig"}). In preliminary studies, no significant differences between cynomolgus α5 404Ala and wild-type α5 were seen, though a slight trend towards increased maximal response was observed.

For the studies shown in [figure 1](#F1){ref-type="fig"}, the HEK tsA201 cells were maintained in Dulbecco Modified Eagle Medium (DMEM, high glucose) (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (Hyclone), 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (Life Technologies, Inc.) at 37° C, 5% CO2. 60mm dishes of 50% confluent α4β2 cells were transfected with α5 variants cDNAs using the FuGENE 6 DNA transfection kit (Roche Diagnostics, Indianapolis, IN). The transfected cells were passed onto blackwall/clear-bottom 96-well plate (Costar Corning Incorporated, Corning, NY) the day before testing. Functional cellular assays were conducted on FLEXstation (Molecular Devices, Sunnyvale, CA) bench-top scanning fluorometer similar to Kuryatov et al., *([@R42])*. Membrane potential assay kit (Molecular Devices) was used according to manufacturer's protocol. The Hill equation was fitted to the concentration-response relationship using a nonlinear least-squares error curve-fit method (Kaleidagraph, Synergy Software, Reading, PA): *I(x) = I~max~\[x^n^/(x^n^+EC~50n~)\]*, where *I(x)* is the current measured at the agonist concentration *x, I~max~* is the maximal concentration for the half-maximal response, and *n* is the Hill coefficient.

2.6. CpG conservation between human and NHP models {#S8}
--------------------------------------------------

In addition to polymorphisms in nAChR subunit genes that may modify nicotine dependent phenotypes, differences in epigenetic regulation between model species are likely to modify complex behaviors and diseases. The field of epigenomics is rapidly expanding as next generation sequencing and high throughput technologies have been adapted to measure covalent modifications of DNA and histones. Both gene-specific and genome-wide approaches ([@R6]) have been utilized in non-human primate models including differences between genetically similar primate species (i.e. human and chimpanzee or human and macaque) that may help explain species-specific traits and diseases. One common approach is to measure methylation of CpG islands, as these CpG dense clusters of DNA often co-locate with the promoter regions of genes and are thought to be associated with differential gene expression. DNA methylation of promoter CpG islands has been measured in only a few nAChR subunit genes.

We therefore performed an analysis of CpG island conservation between humans and rhesus macaque at nAChR subunit genes. In brief, we performed base-wise intersection of human CpG islands with CpG islands annotated for the publically available rhesus genome drafts (rheMac2 or rheMac3) using UCSC defined CpG islands (GC content \>50%, span greater than 200 bp, and a greater ratio of CG dinucleotides in the segment than expected based on C and G content). In human (hg19) we observed a total of 19 CpG islands within 20kb of any nAChR subunit gene (6 at *CHRNA4*; 4 at *CHRNB2*; 2 each at *CHRNA2, CHRNA3*, and *CHRNA7*; and 1 each at *CHRNB4*, *CHRNA10*, and *CHRNA5*). We observed conservation or partial conservation in 15/19 human nAChR CpG islands. However, neither rheMac3 (Chinese-origin) or rheMac2 (Indian-origin) drafts contains complete information for the 15 rhesus conserved CpGs due to gaps in these assemblies. Therefore, until a more complete genome for rhesus, and similarly other NHP models, is available caution must be applied when interpreting these results ([@R76]). However, the similar structure of CpG islands in and around these genes between primate species is supported by the high level of DNA sequence homology described above, especially in the coding and promoter regions. An example of this analysis shows the CpG homology between human and rhesus α4 and β2 genes.

To date differential methylation has been observed within the nAChR 15q25 susceptibility locus in human lung cancer ([@R62]; [@R55]), in *CHRNA4* in mouse tissues relative to brain, and at *CHRNA5* in association with childhood adversity and its interaction with nicotine and alcohol dependency ([@R73]; [@R75]). The levels of methylation in nAChR subunit genes in non-human primate models has yet to be described although this epigenetic modification is expected to account for at least 12--18% of differential gene expression between primate species ([@R31]).

3. Nicotinic receptor expression in non-human primate brain {#S9}
===========================================================

Our knowledge of the distribution of nAChRs in the central nervous system has primarily come from studies using *in situ* hybridization (ISH) and autoradiography. ISH has the advantage of specificity to detect individual mRNA subunits but does not provide information at the protein level. Conversely, autoradiography allows for detection of functional receptor proteins but can lack specificity as many of the available radio-labeled ligands for autoradiography bind to multiple receptor subtypes, though this problem has been alleviated with the identification of conotoxin ligands with increased specificity. The next two sections will review what is known about distribution of nAChR subunit mRNA and functional protein receptors in non-human primates.

3.1. Non-human primate nAChR mRNA distribution {#S10}
----------------------------------------------

In 2000, the Changeux lab conducted a systematic survey of nAChR subunit mRNAs in the brain of adult *Macaca mulatta* (Rhesus macaque) as measured by *in situ* hybridization ([@R28]). Signal was detected in multiple brain areas for all of the subunits tested which included α2-α7 and β2-β4. Across all brain regions measured, the signal intensity was greatest for β2 followed by α4 and α2. These three subunits were detected in the majority of areas surveyed while α3 and β4 were detected only in hippocampus and epithalamus. This is in partial agreement with an earlier study which examined α3 mRNA distribution in *Macaca fascicularis* (cynomolgus macaque) and demonstrated strongest α3 signal in the dentate gyrus, pineal gland, dorsal lateral geniculate, and medial habenula ([@R16]). In rhesus macaque, the α7 subunit was barely to moderately detectable in isocortex, in parts of the mesencephalon and epithalamus, and in nuclei of the thalamus and was strongly expressed in the dentate gyrus of the hippocampal formation and the supraoptic nucleus of the hypothalamus and in the lateral habenula. Localization of the α5 subunit was similar to α7 with the exception of being undetected in the hippocampal formation or epithalamus. Lastly, β3 was strongly detected in substantia nigra, pars compacta and weakly evident in the ventral tegmental area and hippocampal formation ([@R28]). Curiously, α5 was not detected in rhesus habenula, but this may have reflected technical issues with the probe used for hybridization.

A similar study on the distribution of α4, α6, α7 and β2-β4 nAChR subunit mRNAs in adult male squirrel monkeys (*Saimiri sciureus*) was also published by Quik et. al in 2000 ([@R59]). Expression and localization of the α6, α7 and β3 mRNA subunits was similar between the two studies with strongest expression of both subunits in the medial habenula and substantia nigra. The α4 subunit was widely distributed in the brains of both species however the level of expression as measured by signal intensity following *in situ* hybridization was not consistent between the two studies. In squirrel monkeys the strongest signal for α4 was in sub-regions of telencephalon while the signal in this area in macaque was weak and vice versa for nuclei of the thalamus. A further discrepancy is the widely distributed and high expression of β4 subunits in squirrel monkey with expression in macaque limited to the medial habenula and pineal gland. Lastly, the expression of β2 subunits was much stronger in macaque relative to squirrel monkey. Possible explanations for these discrepancies include true differential expression across these two species, age or gender differences of the animals studied, as well as artifactual differences due to probe design, hybridization strength, and detection methods used. Though there were differences between the two studies, importantly as pointed out by Quik et al ([@R59]), overall the distribution of nAChR expression in NHP brain was significantly more similar to that of human expression than was rodent. Analysis of nAChR expression as measured by radioligand binding is discussed below.

3.2 Analysis of nAChR expression by positron emission tomography (PET) {#S11}
----------------------------------------------------------------------

The localization and pharmacokinetics of nAChR in primate brain is a subject of intense study with the emergence of new PET radioligands that bind with subunit specificity. While several radioligands targeting α4β2\* and α7 receptors have been developed and tested in non-human primates, they often demonstrate kinetic profiles that are still not ideal for widespread diagnostic use in humans ([@R35]). For α4β2\* receptors, the greatest level of radioligand uptake and binding occurred in the anteroventral thalamus, lateral geniculate nucleus and midbrain tegmental nuclei; other brain regions expressing significant binding included cortex (insula, temporal, cingulate, frontal), subiculum and striatum ([@R33]; [@R35]). For α7 receptors, distribution was highly concentrated in thalamus, insular cortex, hippocampus and cerebellum, with binding also reported in other cortical regions (occipital, temporal, frontal) and the striatum ([@R30]; [@R34]). PET scans largely mirrored earlier work characterizing the regional distribution of α4β2\* and α7 receptors in monkey brain via receptor autoradiography ([@R40]; [@R29]).

4. Nicotine administration in non-human primate models {#S12}
======================================================

4.1 Changes in CNS nAChR expression in response to nicotine {#S13}
-----------------------------------------------------------

Over the past several years Quik and colleagues have developed and investigated a model of chronic nicotine treatment in squirrel monkeys that involves introduction of nicotine (up to a final concentration 650 µg/ml) in sweetened drinking water. This exposure paradigm is designed to mimic the intermittent and chronic delivery of nicotine as occurs with smoking, and is reported to yield plasma nicotine levels on the lower end of those observed in human smokers (60 -- 90 nM) ([@R49]). Although nicotine intake is involuntary, this model has proven fruitful in characterizing nAChR binding sites and function in primate brain following chronic treatment, particularly in regions associated with nicotine addiction. Some of the earliest reports using this model demonstrated both an enhanced nicotine-evoked dopamine release from synaptosomes and an increased number of α4β2\* nAChR binding sites in the nucleus accumbens and striatal subregions following chronic nicotine exposure ([@R50]; [@R51]). This enhanced binding is consistent with the upregulation of α4β2\* receptors reported in the postmortem cortex and other brain regions of smokers ([@R8]; [@R13]) and in a comparison of smokers versus non-smokers using a subtype-specific PET radioligand ([@R52]). Notably, chronic nicotine treatment exhibits at least some selectivity in upregulating α4β2\* bindings sites, as either no change or a decrease in α3/α6β2\* sites were detected ([@R50]; [@R51]). This selectivity likely reflects the high occupancy rates and desensitization of α4β2\* receptors that is observed in cigarette smokers ([@R14]).

4.2 A non-human primate model of nicotine self-administration {#S14}
-------------------------------------------------------------

Studies to date in non-human primates have focused on changes in nAChR binding sites consequent to nicotine exposure. Our identification of a non-synonymous SNP in the α5 receptor subunit in cynomolgus monkeys that is homologous to the D398N mutation in humans (rs16969968) affords the unique opportunity to study the influence of α5 subunit on drug taking behavior in a primate model. Individuals homozygous for α5N have an increased risk for nicotine addiction, smoke more cigarettes per day, exhibit an earlier age of onset for tobacco use and have greater difficulty in quitting ([@R10]; [@R12]; [@R25]; [@R71]; [@R53]). We hypothesized that cynomolgus monkeys with this mutation would exhibit a differential behavioral sensitivity to nicotine across a range of drug concentrations and would self-administer greater amounts of nicotine under a chronic, open access condition when compared to wild-type animals. To address this question, we developed a two-bottle choice self-administration procedure with oral nicotine that was based largely on earlier work in the development of non-human primate models of ethanol self-administration ([@R69]; [@R27]).

In brief, animals were acclimated to a 14-hr/10-hr light/dark schedule (light on at 0800 hrs) in cages with an operant panel over a 3-month period. During this time all subjects were trained to consume water from two drinking spouts, obtain 1-g banana-flavored pellets from a food receptacle, and present their leg for awake venipuncture to measure plasma nicotine as previously described ([@R69]; [@R27]). For the duration of the study, single daily 22-hour sessions were conducted 6 days/week. All sessions began at 12 noon and ended at 10am the following morning. Within each session, a set food ration was administered over three meals that were scheduled during the first, third, and fifth hours. Meal times were signaled by red stimulus lights (3-light array positioned above each spout), and subjects were required to pull a dowel and finger poke for the delivery of each food pellet. Drinking spouts were accessible anytime during the session (fluid availability was not linked to pellet delivery) and were controlled by solenoid valves. Both valves were opened following a dowel pull (and activation of green stimulus light), but once fluid was chosen from one spout the opposite spout was inactivated until the dowel was pulled again to provide a subsequent choice between drinking spouts. Fluid was continuously available from an activated spout as long as the dowel remained pulled. Sessions were run Monday thru Saturday (i.e., 6 days/week). On Sunday, water was the only fluid available, and food was delivered directly to the animal by technical staff. Cumulative records of fluid intake from each spout were monitored by weight displacement from reservoirs via a computer interface using National Instruments hardware and LabView software (accuracy to 0.1 ml and 0.1 second, over the entire 22-hour session). From this record, drinking within a given increment of time (e.g., hourly) could be derived.

Genotyping of male cynomolgus monkeys (5--6 years old) yielded five subjects that were homozygous or heterozygous wild-type (collapsed as 'α5' group) and two subjects homozygous for α5 398N ('α5N' group). Following acclimation and panel training, all subjects were provided a choice between a nicotine solution (sweetened with 10% w/v maltose/dextrin; M/D) and water. The nicotine solution was always presented on the same spout for a given subject, but its placement was counterbalanced between left and right sides across subjects. In experimental Phase I, the nicotine spout contained M/D alone for 6 days (Monday-Saturday), and then M/D plus nicotine in incrementally greater concentrations (25- to 750 µg/ml) for 6 days each. The seventh day of each week (Sunday) was a "washout" day with access to water only. Thus, each nicotine concentration was available continuously for 1 week (excluding Sunday), and the next highest concentration was started each Monday. During this experimental phase a 500-ml cutoff for the nicotine solution was instituted to prevent intake of hazardous levels of nicotine and the conditioning of a nicotine aversion. The nicotine solution was available continuously for 22-hours, or until the cutoff was reached, whichever came first. Phase I of the study lasted 9 weeks, until each concentration had been tested for six consecutive days. Subjects exhibited a prototypical inverted-U concentration-response curve with maximal mg/kg nicotine intake occurring with access to the 500 µg/ml solution ([Figure 3A](#F3){ref-type="fig"}). A two-way repeated measures (RM) analysis of variance (ANOVA) detected a significant main effect of nicotine concentration on mg/kg intake \[F(7,35) = 7.19; *p* \< 0.001\], but neither a main effect of genotype nor a concentration x genotype interaction were apparent. Based on our *a priori* hypothesis that α5 receptor genotype would alter the behavioral sensitivity to nicotine in a concentration-dependent manner, genotype comparisons at each nicotine concentration were subsequently conducted with separate t-tests. In general, α5N subjects consumed low doses of oral nicotine (≈ 5 mg/kg) when concentrations of 300 µg/ml and less were offered, but consumed comparable doses as α5 wild-type subjects with concentrations of 400 µg/ml and greater. When analyses were run for each concentration, t-tests revealed that α5N subjects consumed significantly less nicotine than wild-types when the 100 µg/ml (t = 4.05; *p* \< 0.01) and 200 µg/ml (t = 2.82; *p* \< 0.05) concentrations were offered ([Figure 3A](#F3){ref-type="fig"}).

In order to ascertain whether genotype influenced the intake of M/D vehicle (i.e., 0 µg/ml nicotine) and to compare nicotine and water intakes, the volume consumed at each spout was examined. The volume of M/D vehicle consumed did not differ as a function of genotype ([Figure 3B](#F3){ref-type="fig"}). A two-way RM ANOVA determined a main effect of nicotine concentration \[F(8,40) = 7.56; *p* \< 0.001\] as well as a genotype x concentration interaction \[F(8,40) = 3.30; *p* \< 0.01\] for the volume of nicotine solution self-administered. Consistent with the mg/kg nicotine intake findings, nicotine solution volumes consumed at the 100, 200 and 300 µg/ml concentrations were significantly decreased in the α5N subjects (all *p'*s \< 0.05) when compared to wild-type animals ([Figure 3B](#F3){ref-type="fig"}), as determined by the Holm-Sidak multiple comparisons procedure. In contrast, a two-way RM ANOVA revealed no effect of nicotine concentration, genotype or their interaction on the volume of water consumed ([Figure 3C](#F3){ref-type="fig"}). These concentration-response relationships indicate that α5N mutants likely express a reduced behavioral sensitivity to oral nicotine.

Immediately following the presentation of the 750 µg/ml nicotine solution and a single washout day, experimental Phase II was initiated. During this phase the volume cutoff for the nicotine solution was removed and animals were maintained on 400 µg/ml nicotine over an additional 11-week period. Levels of plasma nicotine measured every other week throughout Phase II ranged from 100 -- 600 nM and were highly correlated with mg/kg nicotine intakes that occurred between the session start and blood sampling 3-hrs into the session (r = 0.838, *p* \< 0.0001, n = 31). These plasma nicotine levels are consistent with the peak blood levels of 200--400 nM observed in humans during active smoking ([@R49]; [@R60]; [@R7]). Although the α5N animals consumed on average 25% greater mg/kg nicotine per 22-hr session than wild-type animals throughout these 11 weeks, a two-way RM ANOVA showed no significant effect of week, genotype or factorial interaction for mg/kg nicotine intake per session ([Figure 4A](#F4){ref-type="fig"}). In order to determine whether genotype influenced the diurnal pattern of nicotine self-administration hourly nicotine intakes across the 22-hr sessions were plotted ([Figure 4B](#F4){ref-type="fig"}). A 2-way RM ANOVA detected only a main effect of hour \[F(21,105) = 3.12; *p* \< 0.001\]. A couple observations regarding pattern were worth noting. First, α5 wild-type subjects consumed the vast majority of their daily nicotine dose in conjunction with meals scheduled during the 1st, 3rd and 5th hours of the drinking session whereas the α5N animals self-administered nicotine in a pattern independent of meals. Second, α5N animals consistently consumed 0.5 mg/kg nicotine or more per hour throughout the first half of the dark phase whereas intake by the α5 wild-type subjects rarely occurred beyond the initial two hours of lights out.

A separate ANOVA of area under the curve (AUC) for nicotine intake during session hrs 7--20 ([Figure 4C](#F4){ref-type="fig"}) revealed a trend towards increased dark phase consumption in α5N compared to α5 wild-type animals \[F(1,5) = 3.84; *p* = 0.10\]. This latter finding is consistent with observations that a greater degree of nicotine dependence is associated with shorter sleep duration in humans ([@R18]) and that nicotine dependence is associated with a reduction in the disparity between light and dark phase rates of self-administration in rodents ([@R54]).

In summary, our data to date suggest that α5N animals may express a reduced behavioral sensitivity to oral nicotine solutions. This interpretation is consistent with earlier *in vitro* studies showing that the D398N mutation is associated with a hypo-functional α5 receptor; including a decreased nicotinic agonist-evoked intracellular calcium response ([@R66]) as well as a reduced calcium permeability and heightened desensitization when the α5 subunit is an accessory to α4β2\* receptors ([@R41]). Changes in α5 receptor function due to gene variants are particularly relevant for nicotine self-administration given the recently described role for habenular α5 nAChRs in mediating nicotine reinforcement and aversion ([@R23]; [@R24]). There are a few possible explanations for the absence of significant genotype effects on the maintenance of nicotine self-administration in experimental phase II. First, the 400 µg/ml concentration of nicotine was selected because it represented the inflection point in which α5N animals self-administered comparable amounts of nicotine as the α5 wildtype subjects ([Figure 3A](#F3){ref-type="fig"}). It is possible that selection of a higher (or more aversive) nicotine concentration would have unveiled a greater influence of the D398N mutation. Second, the duration of chronic nicotine self-administration was likely insufficient to capture the full development of a nicotine dependence. Subtle, yet incremental, shifts in the nicotine consumption patterns of α5N animals across weeks (e.g., number of intake bouts per session) was indicative of a drinking phenotype that continued to evolve (data not shown). Lastly, inclusion of additional α5N subjects would have provided greater statistical power for the detection of genotype effects for this complex behavior. Overall this data, combined with the high homology of NHP nAChR to human nAChR supports the utility of non-human primates in evaluating the pathophysiology of nAChR and particularly the utility of NHP in the development of more effective drugs for smoking cessation.

5. Conclusions {#S15}
==============

The high homology of non-human primate nicotinic receptors to human nicotinic receptors combined with the high degree of neuroanatomic homology between humans and monkeys provides unique advantages of monkey models for studying roles of nicotinic receptors in complex behaviors. In addition, the high degree of structural homology between monkey and human nAChR suggests that evaluation of efficacy of drugs for which primate models exist such as Parkinson's disease, and nicotine or alcohol self-administration is likely to be predictive of treatment outcomes in humans. Conservation of genomic characteristics such as CpG islands and polymorphisms also demonstrates the utility of NHP models for human personalized medicine treatment developments. These advantages have to be balanced by expense and complexity of non-human primate models. Other disadvantages of NHP include lack of genetic models, though recent advantages in gene transfer and gene modification technologies are beginning to mitigate these limitations.
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![Expression of (α4β2)~2~α5 nAChRs in a human α4β2 concatamer HEK cell line transiently transfected with cynomolgus α5 variants\
The figure represents the combined results of three different transfections. For transient transfections, 60-mm dishes of a 50% confluent human β2QAPα4 cell line were transfected with 2µg of α5 cDNAs using the FuGENE 6 DNA transfection kit. After 24 h, cells were plated onto black 96-well plates for the FLEXstation. Three days after transfection nAChR function was determined in the cell lines using a FLEXstation (Molecular Devices, Sunnyvale, CA) bench-top scanning fluorometer and a membrane potential-sensitive fluorescent indicator as described by Kuryatov et al. ([@R42]). Responses were normalized to the wild type response to 100µM ACh. Results showed that the α5 404-Ala mutant had essentially similar functional properties as the wild type. \* Responses of the α5 398-Asn, 346-Lys mutant to 100 µM were statistically different from wild type (Student test p \<0.05). (Cyno = cynomolgus monkey)](nihms661887f1){#F1}

![CpG island conservation between human and rhesus macaque nAChR subunits\
Human CpG islands are partially conserved across nAChR subunit genes in rhesus macaque. For example in CHRNA4, rhesus CpG islands aligned with 5 of 6 human CpG clusters and in CHRNB2, rhesus CpG islands overlapped 3 of 4 human CpG islands.](nihms661887f2){#F2}

![Nicotine concentration-dependent nicotine self-administration\
Nicotine intake is reported as dose (mg/kg/session; panel A) or volume (ml/kg/session; panel B) and concurrent water intake as volume (ml/kg/session; panel C). In each case, data points depict mean ± SEM of 6-session averages for wild-type (α5, n = 5) and homozygous 398N mutant (α5N, n = 2) subjects. \#p ≤ 0.05 and \#\#p ≤ 0.01 versus wild-type.](nihms661887f3){#F3}

![Chronic nicotine self-administration (phase II). In panel A, nicotine intake (mg/kg/session) with open access to a 400 µg/ml nicotine solution across an 11-week maintenance period is depicted. Each data point represents a 6-day average of intake for the 22-hr sessions conducted per week. In panel B, the diurnal pattern of nicotine intakes (mg/kg/hr) across the 22-hr sessions is illustrated. Each data point illustrates the average hourly intake that occurred throughout all sessions run in weeks 8, 9 and 11 (week 10 data omitted due to ketamine dosing of all subjects for an MRI procedure). Session time between the two dashed vertical lines indicates the dark phase of the light cycle. In panel C, an area under the curve (AUC) analysis of dark phase nicotine intake (same values as hrs 7--20 in panel B) is shown. All data points or bars represent the mean ± SEM of wild-type (α5, n = 5) and homozygous 398N mutant (α5N, n = 2) subjects.](nihms661887f4){#F4}

###### 

Genomic structure of nAChR subunit genes in human (hg19) compared with *macaca mulatta* (rheMac2/3)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene ID                 Assembly                                       RefSeq ID   chr.                                        Ex.1\                                       Intron    Ex. 2     Intron                                  Ex. 3                              Intron                              Ex. 4     Intron     Ex. 5      Intron          Ex.6 (5)\
                                                                                                                                 5\'UTR/CDS                                                                                                                                                                                                                     CDS/3\'UTR
  ----------------------- ---------------------------------------------- ----------- ------------------------------------------- ------------------------------------------- --------- --------- --------------------------------------- ---------------------------------- ----------------------------------- --------- ---------- ---------- --------------- ---------------
  *CHRNA2*                hg19                                           NM_000742   chr08                                       609[a](#TFN2){ref-type="table-fn"}/**73**   1004      **221**   381                                     **45**                             1996                                **110**   3235       **1015**   1224            **126**/1868

  rheMac2                 XM_002805289.1                                 chr08       536[a](#TFN2){ref-type="table-fn"}/**73**   1009                                        **221**   446       **45**                                  1982                               **110**                             3204      **1015**   1728       **126**/502     

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNA3*                hg19                                           NM_000743   chr15                                       501/82                                      1797      **140**   **114**                                 **45**                             1483                                **110**   14759      **1012**   4520            **129**/1299

  rheMac2/3               not annotated[b](#TFN3){ref-type="table-fn"}   chr7        472/64                                      1809                                        **140**   **114**   **45**                                  1468                               **110**                             8605      **1012**   11950      **129**/1306    

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNA4*                hg19                                           NM_000744   chr20                                       231/76                                      1390      **152**   3132                                    **45**                             286                                 **110**   4947       1375       2789            **126**/3428

  rheMac2                 XM_001114265.2                                 chr10       ?[c](#TFN4){ref-type="table-fn"}            ?[c](#TFN4){ref-type="table-fn"}            **152**   3856      **45**                                  320                                **110**                             3859      1372       3408       **126**/24      

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNA5*                hg19                                           NM_000745   chr15                                       200/**106**                                 14985     **152**   5682                                    **45**                             1624                                **110**   1381       **832**    2455            **162**/2016

  rheMac2                 XM_001108279.2                                 chr07       163/**106**                                 15821                                       **152**   3916      **45**[d](#TFN5){ref-type="table-fn"}   ?[d](#TFN5){ref-type="table-fn"}   74[d](#TFN5){ref-type="table-fn"}   1383      **832**    2752       **162**/446     

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNA6*                hg19                                           NM_004198   chr08                                       356/**79**                                  3147      **140**   5951                                    **45**                             2031                                **110**   **103**    **979**    2535            **132**/542

  rheMac2                 XM_001099152.2                                 chr08       202/**79**                                  3171                                        **140**   5906      **45**                                  1720                               **110**                             **103**   **979**    2559       **132**/537     

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNA9*                hg19                                           NM_017581   chr04                                       139/**64**                                  295       **146**   1237                                    **155**                            11517                               **533**   4564       --                         (**542**/697)

  rheMac2                 XM_001094288.2                                 chr05       95/**64**                                   293                                         **146**   1256      **155**                                 11464                              **533**                             4562      --                    (**542**/434)   

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNA10*               hg19                                           NM_020402   chr11                                       **72/61**                                   1310      **146**   445                                     **155**                            1431                                **533**   667        --                         (**458**/520)

  rheMac2                 XM_001113644.1                                 chr14       **72/61**                                   1268                                        **146**   432       **155**                                 1417                               **533**                             662       --                    (**458**/523)   

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNB2*                hg19                                           NM_000748   chr01                                       **264/64**                                  1353      **146**   **184**                                 **45**                             **421**                             **110**   **821**    **973**    3600            **171**/3945

  rheMac2                 XM_001114439.2                                 chr01       **264/64**                                  1348                                        **146**   **184**   **45**                                  **421**                            **110**                             **821**   **973**    3609       **171**/1161    

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNB3*                hg19                                           NM_000749   chr08                                       **128/52**                                  11118     **152**   1521                                    **45**                             20159                               **110**   963        **883**    3934            **135**/448

  rheMac3                 not annotated[b](#TFN3){ref-type="table-fn"}   chr08       **128/52**                                  12199                                       **152**   1503      **45**                                  15070                              **110**                             694       **883**    2697       **135**/444     

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNB4*                hg19                                           NM_000750   chr15                                       112/**55**                                  5491      **149**   4106                                    **45**                             **102**                             **110**   1130       979        3675            **159**/839

  rheMac3                 not annotated[b](#TFN3){ref-type="table-fn"}   chr7        111/**55**                                  5220                                        **149**   4029      **45**                                  **102**                            **110**                             1148      961        3710       **159**/419     

                                                                                                                                                                                                                                                                                                                                                                

  *CHRNA7*                hg19                                           NM_000746   chr15                                       112/**55**                                  248       **140**   70265                                   **45**                             10440                               **110**   42007      **80**     3621            

  rheMac2                 NM 001032883.1                                 chr07       105/**55**                                  222                                         **140**   70068     **45**                                  10074                              **110**                             44083     **80**     3662                       

                                                                                                                                                                                                                                                                                                                                                                

                          Ex. 6                                          Intron      Ex. 7                                       Intron                                      Ex. 8     Intron    Ex. 9                                   Intron                             Ex.10\                                                                              
                                                                                                                                                                                                                                                                            CDS/3\'UTR                                                                          

                                                                                                                                                                                                                                                                                                                                                                

  *hg 19 CHRNA7* cont     **168**                                        636         **195**                                     962                                         **87**    3570      **110**                                 4604                               **519**/1725                                                                        

  *rheMac2 CHRNA7* cont   **168**                                        632         **195**                                     947                                         **87**    3640      **110**                                 4532                               **519**/471                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The genomic structure of human nAChR subunit genes was compared to the rhesus macaque. The size and distribution of nAChR subunit exons is highly conserved across nAChR subfamilies and tribes, and across species. Size of introns and exons given in base pairs, bold text is used when human and rhesus values are equivalent.

The 5\'UTR of CHRNA2 is split by an intron into two fragments (473 and 136bp in hg19; 421 and 115bp in rheMac2).

There were no RefSeq annotations found in rheMac2 or rheMac3 for these subunits. Exon and intron sizes were determined from manual alignment of human sequences to rheMac2/3 as described in the text.

rheMac2 RefSeq annotation XM_001114265.2 predicted 2 exons upstream of Exon 2. Manual base-checking suggests that neither of these predicted exons align to hsCHRNA4.

rheMac2 RefSeq annotation XM_001108279.2 predicted Exon 3 to be 75 bp. Manual base-checking demonstrates that the last 30 bp align to hsCHRNA5 intron 3 and reveals a gap at the next intron/exon boundary in rmCHRNA4.

###### 

Homology of non-human primate nAChR coding sequences with human *(hg19)*.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene ID                    Amino\     great apes   old world   new world                                                                                           
                             Acids                                                                                                                                   
  -------------------------- ---------- ------------ ----------- ----------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------
  *CHRNA2*                   529        98.9         98.5        97.5        97.9       97.2       96.8       97.0       97.4       95.8       95.5       86.6       83.6

  *CHRNA3*                   505        99.6         99.4        99.8        99.6       98.8       98.4       98.8       98.8       98.6       96.3       94.8       92.9

  *CHRNA4*                   627        98.3         98.7        97.7        97.0       96.5       96.2       96.6       92.7       96.7       87.3       92.6       85.3

  *CHRNA5*                   468        99.1         99.6        98.7        98.7       98.5       98.8       99.2       97.9       96.4       95.8       94.4       89.3

  *CHRNA6*                   494        99.6         99.1        97.6        97.8       96.4       96.4       96.0       97.2       97.0       96.9       88.3       85.6

  *CHRNA7*                   502        100.0        99.8        98.8        99.2       99.0       99.2       98.6       99.0       98.4       99.0       96.8       93.6

  *CHRNA9*                   479        99.2         98.5        99.6        98.7       98.5       98.5       98.3       98.1       98.3       97.9       93.7       91.0

  *CHRNA10*                  466        99.1         99.1        98.9        98.7       96.7       96.7       96.9       96.9       96.7       96.0       93.8       92.6

  *CHRNB2*                   502        100.0        100.0       99.0        99.4       99.2       99.0       99.4       99.6       98.2       98.2       94.0       94.4

  *CHRNB3*                   458        99.8         99.6        98.3        99.1       98.4       99.1       98.4       97.6       98.0       98.7       92.3       87.0

  *CHRNB4*                   498        98.1         99.0        97.5        98.2       95.7       96.1       95.3       95.9       92.0       93.3       89.5       83.1

                                                                                                                                                                     

  ***Average similarity***   **99.2**   **99.2**     **98.5**    **98.6**    **97.7**   **97.7**   **97.7**   **97.4**   **96.9**   **95.9**   **92.4**   **88.9**   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ClustalW alignment of human and non-human primate nAChR coding sequences demonstrates greater than 95% homology with human for the majority of NHP species assessed, compared to an average of 88.9% homology for human with mouse. CHRNB2 and the ancestral subunit, CHRNA7, displayed the greatest homology to human across NHP families. The cynomolgus and rhesus macaques, commonly used for biomedical research, were 99.6% homologous to each other over all subunits (data not shown) and 97.7% homologous to human across nAChR coding sequences. Genomic assembly used shown in parentheses.

###### Highlights

-   Genomic structure of macaque nAChRs are compared to human.

-   Non-human primate nAChR coding sequences are compared to human.

-   Cynomolgus monkeys are shown to express an α5 Asp398Asn polymorphism like humans.

-   Monkeys can be trained to self-administer nicotine in multiple paradigms.

-   The α5 Asp398Asn polymorphism affects nicotine self-administration in monkeys.
